In Vitro Release and Stereoselective Disposition of Flurbiprofen Loaded to Poly (D,L-lactide-co-glycolide) Nanoparticles in Rats

Chirality

Volumn 16, Issue 2, 2004, Pages 119-125

  Radwan, Mahasen A ^a   Aboul Enein, Hassan Y ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Enantiomers; Flurbiprofen; Nanoparticles; Pharmacokinetics; Poly(lactide co glycolide); Rats

Indexed keywords

FLURBIPROFEN; NANOPARTICLE; PHOSPHATE; POLYGLACTIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHIRALITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; DRUG FORMULATION; DRUG RELEASE; EMULSION; EVAPORATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY; SUSTAINED RELEASE PREPARATION; VALIDATION PROCESS;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; FLURBIPROFEN; LACTIC ACID; MALE; NANOTECHNOLOGY; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; RATS; RATS, WISTAR; STEREOISOMERISM;

EID: 1642457330     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/chir.10314     Document Type: Article

References (38)

1. Tice L. Long acting biodegradable steroid microcapsules for parenteral administration. Polym Reprints 1985;26:198-199.
2. Langer R. New method of drug delivery. Science 1990;240:1527-1533.
3. Danckwerts M, Fassihi A. Implantable controlled release drug sytem: review. Drug Dev Ind Pharm 1991;17:1465-1502.
4. Leong KW, Langer R. Polymeric controlled drug delivery. Adv Drug Del Rev 1987;1:199-233.
5. Jalil It. Biodegradable poly(lactic acid) and poly (lactide-co-glycolide) polymer in sustained drug delivery. Drug Dev Ind Pharm 1990;16:2353-2367.
6. Brannon-Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int J Pharm 1995;116:1-9.
7. Allémann E, Leroux JC, Gurny R. Biodegradable nanoparticles of poly(lactic acid) and poly (lactic-co-glycolic acid) for parenteral administration. In: Lieberman HA, Rieger MM, Banker GS, editors. Pharmaceutical dosage forms: disperse Systems. New York: Marcel Dekker; 1998, p 163-193.
8. Kawashima Y, Yamamoto H, Takeuchi H, Hino T, Hiwa T. Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. Eur J Pharm Bio Pharm 1998;45:41-48.
9. Rodrigues JM Jr, Fessi H, Bories C, Puisieux F, Devis-Saguet JP. Primaquine-loaded poly(lactide) nanoparticles: physicochemical study and acute tolerance in mice. Int J Pharm 1995;126:253-260.
10. Scholes PD, Coombes AGA, Illum L, Davis SS, Vert M, Davies MC. The preparation of sub-200-nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery. J Control Rel 1993;25:145-153.
11. Smith A, Hunneyball IM. Evaluation of poly(lactic acid) as a biodegradable drug delivery system for parenteral administration. Int J Pharm 1986;30:215-220.
12. Vert M. Structure et comportement des polymères. Exemples des polymères biorèsorbables. STP Pharma 1987;3:216-222.
13. Vert M, Schwach G, Engel R, Coudane J. Something new in the field of PLA/GA bioresorbable polymers. J Control Rel 1998;53:85-92.
14. Aboul-Enein HY, Wainer IW. The impact of stereochemistry on drug development and use. New York: Wiley; 1997.
15. Day RO, Brooks PM. Variations in response to non-steroidal antiinflammatory drugs. Br J Clin Pharmacol 1987;23:655-658.
16. Brune K, Beck WS, Geisslinger G, Menzel-Soglowek S, Peskar BM, Peskar BA. Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition. Experientia 1991;47:257-261.
17. Wechter WJ, Leipold DD, Murray ED Jr, Quiggle D, McCracken JD, Barrios RS, Greenberg NM. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 2000;60:2203-2208.
18. Wechter WJ, Murray ED Jr, Kantoci D, et al. Treatment and survival study in the C57BL/6J-APC(Min)/+(Min) mouse with R-flurbiprofen. Life Sci 2000;66:745-753.
19. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Int Med 1999;159:161-166.
20. Wechter WJ, Kantoci D, Murray ED Jr, et al. R-Flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res 1997;57:4316-4324.
21. Jamali F, Berry BW, Tehrani MR, Russell AS. Stereoselective pharmacokinetics of flurbiprofen in humans and rats. J Pharm Sci 1988;77:666-669.
22. Berry BW, Jamali F. Enantiomeric interaction of flurbiprofen in the rat. J Pharm Sci 1989;78:632-634.
23. Knihinicki RD, Day RO, Graham GG, Williams KM. Stereoselective disposition of ibuprofen and flurbiprofen in rats. Chirality 1990;2:134-140.
24. Jamali F, Berry BW, Wright MR. Dose-dependency of flurbiprofen enantiomer pharmacokinetics in the rat. J Pharm Sci 1994;83:1077-1080.
25. Hubbard JW, Srinivas NR, Quinn D, Midha KK. Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder. J Pharm Sci 1989;78:944-947.
26. Avgerinos A, Noormohammadi A, Hutt AJ. Disposition of ibuprofen enantiomers following the oral administration of a novel controlled release formulation to healthy volunteers. Int J Pharm 1991;68:97-103.
27. Davies NM. Clinical pharmacokinetics of tiaprofenic acid and its enantiomers. Clin Pharmacol 1996;31:331-347.
28. Inotsume N, Iwaoka T, Honda M, et al. Pharmacokinetics of nicardipine enantiomers in healthy young volunteers. Eur J Clin Pharmacol 1997;52:289-292.
29. Busse D, Fromm M, Morike K, Drescher S, Kuhlkamp V, Eichelbaum M. Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. Clin Pharmacol Ther 2001;69:324-332.
30. Boulton DW, Fawcett JP. The pharmacokinetics of levosalbutamol: what are the clinical implications? Clin Pharmacol 2001;40:23-40.
31. Radwan MA. Zidovudine, diclofenac, and ketoprofen pharmacokinetic interactions in rats. J Pharm Pharmacol 2000;52:665-669.
32. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 1985;60:110-111.
33. Gibaldi M, Perrier D. Pharmacokinetics, 2nd editon. New York: Marcel Dekker: 1982.
34. Elkheshen SA, Radwan MA. Sustained release microspheres of metoclopramide using poly (D,L-lactide-co-glycolide) copolymers. J Microencapsulation 2000;17:425-435.
35. Choi HS, Seo S, Khang G, Rhee JM, Lee HB. Preparation and characterization of fentanyl-loaded PLGA microspheres: in vitro release profiles. Int J Pharm 2002;234:195-203.
36. Maggi L, Massolini G, De Lorenzi E, Conte U, Caccialanza G. Evaluation of Stereoselective dissolution of verapamil hydrochloride from matrix tablets press-coated with chiral excipients. Int J Pharm 1996;136:43-51.
37. Wechter WJ, Bigornia AE, Murray ED Jr, Jee WSS. Chiral pharmacokinetics of rac-flurbiprofen and pharmacodynamics of anabolic bone response in the normal rat. Chirality 1994;6:457-459.
38. Cutler DJ. Theory of the mean absorption time, an adjunct to conventional bioavailability studies. J Pharm Pharmacol 1978;30:476-478.